• Worldwide initiatives to slash carbon emissions, recently bolstered by the Inflation Reduction Act in the United States, are underpinned by EV uptake, which needs innovation to scale and reach critical mass
• Hillcrest Energy Technologies has developed a cutting-edge 250-kilowatt, 800-volt Silicon Carbide (“SiC”) EV inverter that has captured the attention of leading firms
• Hillcrest has recently inked new partnerships, including one with a global Tier 1 automotive supplier, for the purpose of commercializing new inverters for electric mobility applications

With 1.4 billion vehicles in use today and around 1 percent of them powered by electricity, the move to decarbonize the transportation industry is accelerating yet also has far to go. The U.S. Inflation Reduction Act signed into law in August is arguably the most significant piece of U.S. legislation designed to accelerate adoption of electric vehicles (“EVs”) and promote innovation, which is going to have to come from all angles to meet global carbon goals in the next eight years. Sure, it’s simple to say, “everyone just needs to get an electric vehicle,” but it is more complicated than that. Consider that the Argonne National Laboratory is constantly analyzing data to try and figure out where to put new charging stations to ensure fair access and that research is still relatively nascent in understanding temperature-related fluctuations in battery performance. And that’s just one observation from a 30,000-foot view. At a more granular level, new power conversion technologies, like those of Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF), are being developed to improve efficiency and curtail EV costs. Hillcrest, a one-time fossil fuels producer, has ditched that model to pivot into clean energy technologies. The company specializes in developing control systems and electric power conversion devices for powertrains and charging applications in addition to renewable energy generation and storage systems. As noted by Hillcrest CEO Don Currie, the company is at an inflection point after developing and successfully testing a cutting-edge 250-kilowatt (“kW”), 800-volt (“V”) Silicon Carbide (“SiC”) EV traction inverter prototype. The inverter’s adaptable design gives Hillcrest a competitive advantage with the flexibility to quickly meet customers’ needs with a smaller, lighter, and more powerful product. “[Our] highly adaptive power conversion technology is at an exciting stage of growth and development, evidenced in part by our two recent strategic partnerships including a global Tier 1 automotive supplier,” said Currie in a recent press release announcing Hillcrest had retained an investor relations firm to help with outreach. In the automotive industry, Tier 1s are operations that supply parts and systems directly to an automaker such as Tesla, Ford, Rivian, Volkswagen, et al. Confidentiality agreements keep Hillcrest from being able to reveal the name of its new Tier 1 partner, but it can disclose that the two have a memorandum of understanding to collaborate to integrate an optimized version of Hillcrest’s 250kW, 800V inverter into a future powertrain system. The goal is commercialization of a nominal 350kW product that capitalizes on the unique properties of Hillcrest’s highly efficient inverter. That news came on the heels of a new partnership with Hercules Electric Mobility, Inc. Hercules, an emerging company revolutionizing electric mobility in both marine and recreational vehicles, is also interested in working with Hillcrest to access its inverter tech. The two are collaborating on building and commercializing a 250kW, 800V inverter optimized for a Hercules electric powertrain. The collaborative agreements speak volumes as to the quality of the Hillcrest technology, as well as the company’s adaptable nature and flexible technology design that facilitates optimization and seamless integration with new products. For more information, visit the company’s website at www.HillcrestEnergy.tech. NOTE TO INVESTORS: The latest news and updates relating to HLRTF are available in the company’s newsroom at https://ibn.fm/HLRTF

• BEAT named winner of the 2022 Cardiovascular Innovations (“CVI”) Innovation Summit and Shark Tank Competition
• Company’s presentation included an overview of its HeartBeam AIMI™ platform, which aids in more precise heart attack diagnosis
• HeartBeam is building an intellectual-property portfolio focused on enabling 12-lead electrocardiogram (“ECG”) diagnostics outside of a medical setting

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, has been named winner of the annual Cardiovascular Innovations (“CVI”) 2022 Innovation Summit and Shark Tank Competition (https://ibn.fm/ftaNr). The annual conference focuses on innovative health solutions for cardiology clinicians who participate in the care of patients with coronary, peripheral and structural cardiovascular diseases; awards presented at the conference recognize state-of-the-art cardiac technologies. “We are proud that HeartBeam has been recognized for our unique approach to heart attack diagnosis,” said HeartBeam CEO and founder Branislav Vajdic, PhD. “Our goal is to provide a solution that offers both healthcare professionals and patients peace of mind regarding their diagnosis and treatment plan.” The company was invited to present at the conference, which was held in Denver on July 21, 2022. The company’s chief business officer, Jon Hunt, PhD, delivered an address entitled “Medical Grade Heart Attack Detection.” The presentation included an overview of the company’s HeartBeam AIMI platform, which aids in more precise heart attack diagnosis. HeartBeam was one of several companies presenting at the conference; the awards were determined by judges that included expert cardiologists along with veterans from leading companies. The company, which has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, has made a mark for itself in the cardiac care field by building an intellectual-property portfolio focused on enabling 12-lead ECG diagnostics outside of a medical setting. Most recently, HeartBeam announced that it was issued a new patent, which enables generation of a synthesized 12-lead ECG by the HeartBeam AIMIGo(TM) credit card-sized device, by the United States Patent and Trademark Office (“USPTO”) (https://ibn.fm/BERLz). “This patent provides additional intellectual property protection for our breakthrough AIMIGo technology offering 12-lead ECG capability in the form of a credit card-sized device with the same footprint as the single-lead products currently in the market today,” said Vajdic. “Our 12-lead AIMIGo technology, which is part of our granted patent, offers the potential to bring a level of diagnostic accuracy consistent with the current 12-lead ECG standard of care. This could reduce the critical time to intervention for heart attack patients, saving lives and reducing healthcare costs by ruling out a heart attack and reducing the number of emergency room visits.” The HeartBeam AIMI-platform technology is anticipated to assist healthcare professionals in identifying patients who present with chest pain to facilitate rapid detection of a heart attack and determine an appropriate treatment regimen. Chest pain is the second most common reason for an emergency-department visit, with high costs associated with these visits. HeartBeam’s technology may offer more accurate heart attack detection to triage patients and expedite treatment. The HeartBeam technology platform has not yet been evaluated by the FDA and is not approved for clinical use in the USA or other global geographies. For more information, visit the company’s website at www.HeartBeam.com. NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

• Cepton signed binding agreement with established automotive lighting tier 1 supplier Koito for investment of $100 million to bolster its next stage of growth
• Agreement penned on October 27, 2022, marks the third investment from this long-term automotive Tier 1 partner and existing shareholder since 2020
• Lidar market expected to grow rapidly to reach $59 billion by 2030; Cepton appears to continue leading as a prominent figure, as it works toward commercialization and mass market deployment of its lidar sensors

Following a previously reported letter of intent from Koito Manufacturing Co., Ltd. (TSE:7276), Cepton (NASDAQ: CPTN) has announced that it has entered into a binding investment agreement for a $100 million investment from its long-term automotive Tier 1 partner and current shareholder (https://ibn.fm/LjTSk). This Silicon Valley innovator and leader in high-performance lidar solutions intends to use this investment — Koito’s third since 2020 — to fund the company’s next growth stage as it looks to execute its vision to scale lidar technology for mass deployment. Under the terms of the Investment Agreement, unanimously approved by Cepton’s board of directors, Koito will purchase $100 million of convertible preferred stock. This stock will be convertible, beginning on the first anniversary of the issue date, into shares of Cepton’s common stock at an approximate initial conversion price of $2.23 per share, representing a 10.0% premium to Cepton’s volume-weighted average price over the trailing 20 trading day period. As well as a 13.4% premium 14.4% 30-day VWAP and a 25.5% 90-day VWAP. The company expects to close the investment in the first quarter of 2023, subject to the approval of Cepton’s shareholders and satisfaction of relevant closing conditions. More information regarding the key terms of the investment is included in a Form 8-K that Cepton recently filed with the US Securities and Exchange Commission (https://ibn.fm/tnrlO). Cepton and Koito have had an established history of collaboration, including one that has been crowned with notable success, such as a significant ADAS lidar series production award on the General Motors business. In September 2022, the company received a Letter of Intent for up to $100 Million investment from this automotive lighting leader to boost Cepton’s balance sheet and its manufacturing and supply chain capabilities to meet the expected increase in demand amid the rapidly growing lidar market. “We are excited to further strengthen our partnership with Koito and remain deeply grateful for Koito’s continued support. This investment solidifies Cepton’s financial position and allows us to continue our execution excellence as we focus on commercialization and mass market deployment of our lidar sensors,” said Dr. Jun Pei, Cepton’s Co-Founder and CEO. Mr. Michiaki Kato, Koito’s President, appears equally enthusiastic about deepening what already looks like a successful collaboration. “We are pleased to announce our third investment in Cepton as we work towards developing and commercializing next-generation automotive sensor technologies. Our partnership has developed over the years and Cepton remains a critical partner for us. This investment serves as a testament to our commitment towards Cepton and bringing lidar-based ADAS and AV systems to everyday vehicles,” he said. While the lidar history goes back to the 1960s, when it was developed for aerospace and defense purposes, it was not until the 2000s that lidars started to be deployed in R&D automotive applications. In recent years, a growing number of players have focused on automotive applications, especially autonomous vehicles (https://ibn.fm/n7w3w). Although lidar used to be expensive, just like many other technologies at the pre-scale stage, the times are rapidly changing as the automotive industry evolves. Nowadays, lidar companies collaborate with leading automakers to make the technology more efficient and affordable, driving the cost down to as little as three digits. For example, Cepton expects to scale its lidar technology through its ADAS lidar series production award with Koito on the General Motors business. Other lidar companies have also announced series production awards from other OEMs. As a result, according to Cepton’s founder and CEO, costs are dwindling across the board (https://ibn.fm/4cLC9). Since 2020, when the autonomy levels started moving towards L3, the lidar industry had been progressing at an accelerated rate, attracting increasing investor attention, and receiving significant investments. It appears that the lidar industry is on the verge of mass-market adoption. High-performance, safe, and affordable lidar is expected to be deployed at a large scale in consumer vehicles — something Cepton has prided itself in as being a frontrunner of safety and efficiency for all classes (https://ibn.fm/c2KWm). As a result, the addressable market for lidar could grow to $59 billion by 2030, of which $50 billion is in ADAS applications. When Dr. Pei founded Cepton in 2016, his vision was to make lidar scalable. With continuous innovations driven by OEM requirements, the company seeks to bring lidar into everyday passenger cars, not just the luxury segment. For more information, visit the company’s website at www.Cepton.com. NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

• Brain injuries affect all aspects of society, from recreational youth athletics to military trauma interventions
• Despite the commonality of brain concussion injuries — more than 5 million a year in the United States alone — no FDA-approved therapy exists
• Medical technology innovator Odyssey Health Inc. is working toward a commercialized product treatment solution to the unmet need of concussion injuries
• Odyssey’s product for treating brain concussion has recently completed a series of human and animal safety trials and is now being prepped for Phase II/III trials focused on proving efficacy
• The product administers neurosteroids across the blood-brain barrier to stop brain swelling following a head injury and is simple enough to be carried in a user’s pockets
• Odyssey formed a pharmaceutical subsidiary to help the company’s push toward product commercialization, and recently announced the expansion of the subsidiary’s executive team to add needed experience

Within the medical community, the tide has turned for individuals treated for physical injuries whose correlate mental deficits were previously largely undetected, undiagnosed, and untreated. Traumatic brain injuries resulting from causes as diverse as playing sports to dealing with explosives are increasingly being recognized as a health hazard that can have serious, though often unrecognized, long-term effects. Nevada-based medical technology solutions innovator Odyssey Health (OTC: ODYY) is helping to lead the search for pharmaceutical solutions for brain injuries that may remain hidden while more apparent bodily wounds are being treated, and recent additions to its executive team demonstrate the company’s expectations of commercializing its much needed products. Odyssey Health’s focus on developing and testing drug candidates to combat conditions with unmet needs has resulted in products such as a device to suck out a foreign obstruction in a choking victim’s throat, and a new solution for detecting heart disease in its early stages. But the company’s flagship development relates to marketable responses to central nervous system ailments, including the highly fatal childhood disease Niemann-Pick type C Disorder, nerve gas exposure and, most notably, brain concussions. In October, Odyssey announced the formation of its subsidiary Odyssey Neuropharma, Inc. — a wholly owned pharmaceutical company focused on the development of Odyssey’s neurosteroid solutions for treating these disorders, using its unique intranasal delivery device coupled with its powdered formulations to allow drugs to be delivered more directly and timely to the brain (https://ibn.fm/NEgom). The formation of Odyssey Neuropharma followed Odyssey’s completion of Phase I clinical testing for the safety of its drug to treat concussion, using its portable, breath-powered device that administers neurosteroidsinto the nasal cavity where receptors can transport them into the central nervous system bypassing the often stubborn blood-brain barrier. The trials found the drug candidate to be well tolerated in human subjects and their data is being communicated to the U.S. Food and Drug Administration (“FDA”) amid plans for a Phase II/III trial that aims to establish the drug’s effectiveness. In the meantime, the company’s executive team expansion includes introducing Odyssey Neuropharma’s new Chief Commercial Officer Erik Emerson and Chief Operating Officer Greg Gironda, whose experience is expected to help Odyssey with the drive toward market readiness. “The opportunity to impact the lives of our military, elderly, children, and athletes was something that one can only hope for in our careers,” Emerson stated in a company news release (https://ibn.fm/kbk7e). “Mild traumatic brain injury and the subsequent long-term effects are a true urgency. Joining the team at this critical juncture to lead our conversion of strong early science, to potential patient availability is unique.” For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• In November 2021, Lexaria laid out its plans for several new and ongoing R&D programs, among them hormone replacement, dementia, rheumatoid disease, and diabetes
• The company has since begun its DIAB-A22-1 study program on the effectiveness of the patented DehydraTECH(TM)-processed CBD for the potential therapeutic utility against diabetes
• Lexaria is optimistic that the study will yield some notable results, particularly with DehydraTECH-CBD having met primary safety and efficacy objectives from its HYPER-H21-4 clinical study on the potential treatment of hypertension
• So far, CBD has shown some ability to reduce the incidence of diabetes in mice, and Lexaria looks to build on these findings and  investigate DehydraTECH’s overall effectiveness for the potential treatment of the disease among human patients
• DIAB-A22-1 marks a notable milestone for Lexaria and is a testament to the company’s commitment to advancing its efforts to address unmet patient needs and create shareholder value

In November 2021, Lexaria Bioscience (NASDAQ: LEXX), a global leader in enhancing the speed and efficiency of orally-delivered fat-soluble active molecules and drugs, announced its plans for several new and ongoing research and development (“R&D”) programs on its patented DehydraTECH(TM) technology for the 2022 calendar year. The study areas included hormone replacement, dementia, rheumatoid disease, and diabetes (https://ibn.fm/yoOng). On November 8, 2022, Lexaria announced that the study program, DIAB-A22-1 began on schedule, making it the company’s first-ever study to investigate whether its DehydraTECH-processed cannabidiol (“CBD”) may potentially have therapeutic utility against diabetes (https://ibn.fm/IH3Ul). This study preceded Lexaria’s first-ever study on DehydraTECH-CBD’s potential for the treatment of dementia, which began one week later and follows the successful HYPER-H21-4 clinical study on the potential treatment of hypertension. According to the Centers for Disease Control (“CDC”), at least 37.3 million people in the United States have diabetes, representing 11.3% of the population (https://ibn.fm/vCk9i). The condition accounts for 31 out of every 100,000 deaths in the country, making it the 7th largest cause of death in the United States. In 2021, it accounted for over 100,00 deaths for the second consecutive year, spurring a call for a federal mobilization as seen before with the fight against HIV/AIDS (https://ibn.fm/mU6OO). Lexaria is optimistic that its DehydraTECH-CBD will yield notable results from this study, especially having met primary safety and efficacy objectives from its HYPER-H21-4 clinical study (https://ibn.fm/bfWzg). There is a strong connection between heart disease, hypertension, and diabetes, with hypertension proving to be as frequent in people with diabetes and hypertensive patients being at greater risk of developing diabetes. So far, CBD has shown some ability to reduce the incidence of diabetes in mice, with the study yielding a significant decrease in pancreatic islets production of destructive insulitis and inflammatory cytokine production (https://ibn.fm/RVtmE). Lexaria looks to build on these findings and investigate whether its patented DehydraTECH-CBD may potentially have therapeutic utility against diabetes. DIAB-A22-1 marks a notable milestone for Lexaria, even as the company aims for late 2022/early 2023 for an Investigational New Drug (“IND”) application with the United States Food and Drug Administration (“FDA”) for DehydraTECH-CBD for the treatment of hypertension. It is also a testament to the company’s commitment to advancing its studies, addressing unmet patient needs, and creating shareholder value. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• RNG is considered carbon-neutral because it is derived from organic sources that produce methane emissions while decaying
• EverGen is developing Canadian RNG infrastructure with projects in British Columbia, Alberta, and Ontario
• EverGen’s expansion projects backed by Canada’s highly regulated energy sector, supported with long-term contracted revenue agreements

According to the United Nations, the future of clean energy depends on fuel sources that are economical and reliable while minimizing carbon emissions (https://ibn.fm/NSl40). Sources with a minimal or zero carbon footprint like liquified natural gas (“LNG”), solar panels, and wind turbines are viable options, however renewable natural gas (“RNG”) provides a stronger impact by removing carbon from the atmosphere. EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF) is dedicated to a net-zero future that leverages renewable energy sources like RNG. The company leads RNG adoption efforts across Canada by acquiring, developing, building, and operating a portfolio of RNG and related waste-to-energy projects while developing a domestic RNG platform. RNG is considered carbon-negative because it is derived from organic sources that otherwise would decay and produce methane emissions. According to the Southern California Gas Company, RNG sourced from landfill-diverted food and green waste can provide a 125 percent reduction in greenhouse gas emissions (https://ibn.fm/XR1Kc). Further, replacing traditional vehicle fuel with RNG sourced from dairy manure can reduce greenhouse gas emissions by 400 percent, according to the utility company. EverGen is committed to expanding RNG infrastructure across Canada by investing in projects in British Columbia, Alberta, and Ontario. The company recently broke ground at its West coast Fraser Valley Biogas RNG expansion project with the goal of doubling RNG production volumes to approximately 160,000 GJ of RNG per year (https://ibn.fm/phvYB). Across the country in Ontario, the company recently acquired a 50 percent interest in Project Radius, which includes three RNG projects collectively capable of producing approximately 1.7 million GJ of RNG per year (https://ibn.fm/PVHxE). “EverGen will deliver on our platform expansion commitments with the potential to exceed 1,000,000 GJ of RNG production annually,” said Chase Edgelow, CEO of EverGen. “Ontario has an abundant amount of excess organic feedstock, and as a leader in the RNG industry, EverGen can develop the sustainable infrastructure that contributes to carbon-negative energy production and the greening of the province.” EverGen’s expansion projects are backed by Canada’s highly regulated energy sector. With the support of long-term contracted revenue agreements, the company can invest in its RNG network through a guaranteed pricing mechanism. “This is different from the US model, which is reliant on carbon credits which have a pricing mechanism that can be difficult to predict,” said Edgelow in a recent interview (https://ibn.fm/ixLJi). “What’s unique about this landscape and industry in Canada comes from what we see as a really strong tailwind for our business:  the strength of the Canadian regulated gas utilities in terms of providing long-term offtake agreements for energy derived from these RNG projects.” Based in Vancouver, British Columbia, EverGen is an established independent renewable energy producer committed to developing Canada’s RNG infrastructure. With projects located across the country, the company is emerging as a leader committed to powering a sustainable, net-zero future based on renewable energy sources. For more information, visit the company’s website at www.EverGenInfra.com. NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

DE&I leaders, executives, and professionals from the pharma, biotech, healthcare, and allied industries, are invited to the 2nd Advancing Diversity Equity & Inclusion (“ADEI”) In Pharma and Healthcare Summit. This online live-streaming event will be held on December 8-9, 2022. The agenda will guide you to move from awareness towards advocacy and action, as you build a culture of representation and inclusion for success in the workplace and clinical trial management. Professionals and industry experts from the medical realm gather on this forum to discuss and explore ways to attain success and improve the patient’s overall experience. This live-streaming event is attended by dignitaries and medical professionals from all over the world. They share valuable insights, get the know-how of trending healthcare issues, and analyze strategies for improved drug R&D, disease awareness, and clinical trial outcomes. The event is hosted by Dynamic Global Events (“DGE”), a life science leader in organizing b2b events. The global event company strives to meet the dynamic informational and networking needs of the pharmaceutical, biotechnology, healthcare, medical devices, and allied industries. Topics being covered at the summit include:

• Build workplace cultures that support different types of people, including LGBTQ
• Work towards the inclusion of disability and neurodiversity in the workplace
• Ensure better DE&I in clinical trials and drug development
• Discuss the best yardstick to measure the scope and durability of change
• Implement a recruiting strategy that aligns with your organization’s goals
• Explore the hurdles of incorporating DE&I in medical research and publishing
• What is the status of ERGs/BRGs in driving a culture of inclusion?
• Discuss the importance of creating a sense of belonging to the different facets of the society
• Initiate employee well-being programs that protect your initiatives and gains

This summit strongly emphasizes the need for inclusivity, belonging, and equality, and demonstrates how these factors positively impact drug R&D, disease awareness, and clinical trial outcomes. There will also be a highlight case study where Pfizer will share insights on the five-point strategy the organization implemented to successfully close the gender gap and reinforce equitable gender distribution. To learn more, please visit https://ibn.fm/pdC20.

• FuelPositive Corp. is a Canadian developer of clean energy solutions, focusing on an on-site system for producing hydrogen-dense green ammonia
• The company’s modular system can produce 300 kg per day (500 liters per day) of liquid anhydrous carbon-free ammonia — the amount needed to fertilize a 2,000-acre farm
• The system’s ability to grant end users greater energy independence as a climate-friendly resource is filling a market need at an opportune time as industries struggle to manage supply chain challenges created by COVID and the ongoing Russia-Ukraine war
• The module is being tested in a pilot project by Canadian farmers and recently became available for pre-sale orders

Clean energy technology developer FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) is proving itself as a thought leader and innovator of climate-friendly farming solutions vital to global economies at a time when conflicts and supply chain interruptions are stressing needed resource markets. FuelPositive’s onsite, containerized, modular system for producing green, hydrogen-dense ammonia is designed to help the fertilizer-dependent agricultural industry and other end users who may want to produce ammonia or hydrogen fuel locally. The war in Ukraine has highlighted for many the need to ensure energy and agricultural independence because of the war’s disruptions of commodities supply chains for international product shipments that normally originate not only in Ukraine but Russia as well (https://ibn.fm/ZoX5I). Nancy Qian, a co-director of Northwestern University’s Global Poverty Research Lab and the Founding Director of China Econ Lab, noted in a recent editorial for Project Syndicate that Western nations are vulnerable to agricultural export problems that exceed the measure of the war’s disruptions. Those vulnerable nations, including the United States, she argued, would do well to increase production and reserves to mitigate the impact of any disruptions both for the sake of political maneuvering and to help stave off mass starvation in economically poorer countries (https://ibn.fm/ro7Di). “The global food system urgently needs to become more resilient for political and humanitarian reasons,” Qian stated. FuelPositive’s system can produce 300 kg per day (500 liters per day) of liquid anhydrous carbon-free ammonia, a hydrogen-dense resource that FuelPositive describes as the approximate amount needed for a 2,000-acre farm’s fertilizer needs. The modular model allows for additional systems to be added on for larger farms. Because the units are portable, fitting inside standard shipping containers, they can provide users’ needs onsite and reduce concerns about the vagaries of supply chain fulfillment. In August, the units became available for pre-sale for interested farmers. In Manitoba, Canadian farmers Tracy and Curtis Hiebert are preparing to use the modular system in the company’s first demonstration pilot project to evaluate its real-world performance over a one-year period. “The FuelPositive system will give us stability. That’s what we like about it. It’s stabilizing the supply and stabilizing the price,” Curtis Hiebert stated (https://ibn.fm/dSDz7). The initial base system price will be CA$950,000, although individual farm conditions may cause variability in the actual price, the company states. FuelPositive also expects that customers can lower their cost to acquire and operate the system by using government clean tech adoption programs. Carbon credits and tax incentives will further offset costs for its customers. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• The presentation focused on BiondVax’s yeast fermentation system to manufacture innovative alpaca-derived recombinant nanosized VHH-antibodies (NanoAbs) and highlighted the company’s NanoAbs as a platform for development of therapeutics addressing diseases with large unmet medical needs and attractive commercial opportunities
• BiondVax’s lead NanoAb candidate, an inhaled COVID-19 treatment, exhibits significant competitive advantages over currently available mAbs and oral COVID-19 therapies
• Development of additional NanoAbs, targeting psoriasis, asthma, psoriatic arthritis and wet macular degeneration is underway via a strategic collaboration with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Gottingen (“UMG”), both in Germany

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases, recently presented at Recent Advances in Fermentation Technology (“RAFT”) 14, a conference of the Society for Industrial Microbiology and Biotechnology (“SIMB”), which took place in Orlando, Florida. RAFT provides a platform for academic and industrial scientists to discuss the latest developments in fermentation technology. BiondVax’s Head of Technical R&D, Dr. Dalit Weinstein Fischer, presented the company’s Nano-sized solution for a massive challenge: NanoAbs as a platform for COVID-19, asthma, and psoriasis therapies at the Caribe Royale Orlando on November 8, 2022 (https://ibn.fm/ziT4B).

The RAFT presentation focused on BiondVax’s yeast fermentation system to manufacture innovative alpaca-derived recombinant nano-sized NanoAbs (aka VHH-antibodies and nanobodies). NanoAbs are a “bio-better” category of monoclonal antibodies (“mAbs”) providing several key advantages vs. currently available mAb therapies. These advantages include speed of discovery and production (important for newly emerging infectious diseases), smaller molecule (which suggests a better safety profile with fewer side effects), lower cost of production, greater thermostability (usually translates to longer shelf life), better ability to sustain shear forces (which allows for various routes of administration such as inhalation), much higher affinity to their molecular target (which could translate to lower required dose and possibly better efficacy at a given dose), and potentially enhanced patient convenience (e,g, self-administered inhalation at home, and lower adverse effects). The company’s lead NanoAb candidate for treating COVID-19 exhibits significant competitive advantages over currently available mAbs and oral COVID-19 therapies.

BiondVax is uniquely positioned to advance nano-sized antibody innovation from R&D through commercialization via top-tier pharma leadership, extensive drug development expertise, in-house GMP biologics production facility, and collaboration with Max Planck and UMG.

BiondVax is developing additional NanoAbs to address diseases with large unmet medical needs and attractive commercial opportunities, likely beginning with psoriasis and asthma. Psoriasis is an autoimmune inflammatory disorder that results in the overproduction of skin cells, leading to an itchy, red skin condition that presents with inflammation, lesions, and plaque formation.

The psoriasis treatment market was valued at $24.33 billion globally in 2021 and is projected to grow from $26.37 billion in 2022 to $47.24 billion by 2029, at a CAGR of 8.7% during the forecast period. According to the National Psoriasis Foundation (“NPF”) estimations, around 125 million patients globally suffered from psoriasis in 2020, with a prevalence between 1.5% and 5% in developed countries (https://ibn.fm/ciyBo).

BiondVax’s drug development expertise stems in part from its past experience with the development of a novel universal flu vaccine licensed from the Weizmann Institute of Science Lab of Professor Ruth Arnon, known for being the co-developer of Copaxone, Teva Pharmaceuticals’ block buster multiple sclerosis drug. During development of its prior vaccine candidate, BiondVax conducted seven phase 1/2 and phase 2 clinical trials in Israel, Europe, and the USA, and a seven-country pivotal Phase 3 trial conducted from 2018 to 2020 that was completed on-time and on-budget.

BiondVax is a public company traded on Nasdaq with the ticker BVXV. 21% of its shares are held by the cyber security mogul Marius Nacht, the founder of the world leading cyber security company CheckPoint (NASDAQ: CHKP).

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• While governmental leaders continue to work toward measurable climate progress, U.S.-based Correlate Infrastructure Partners Inc. is helping corporate clients attain ESG successes sought by investors
• The company recently reported that completion of construction milestones in contracted projects has netted it an 877 percent jump in revenues from Q2 to Q3, amounting to a 15,024 percent increase YOY
• CIPI’s efforts include helping clients achieve significant yet affordable change in their facilities’ utilities usage through improvements to mechanical, electrical, and plumbing processes, the addition of solar upgrades, water optimization, and other strategic measures

Nearly a decade has passed since world leaders agreed to pursue pollution reduction strategies to keep global temperature increases from peaking at more than 1.5 degrees Celsius above the planet-wide temperature peaks recorded nearly 300 years ago, and many climate policy makers who gathered this month for the latest United Nations-sponsored Conference of the Parties (“COP27”) climate change conference expressed concerns that not enough has been done to adhere to the agreement (https://ibn.fm/q0HDx). While U.S. President Joe Biden and Chinese President Xi Jinping declared Nov. 14 they would set aside disagreements over some of the countries’ policies enough to work together on fighting climate change, protecting global health and safeguarding access to food, many industries are also doing their part to show environmental, social and governance (“ESG”) responsibility in order to appeal to investors (https://ibn.fm/MK8lv). Correlate Infrastructure Partners (OTCQB: CIPI), a U.S. company that advises the commercial real estate industry (companies that develop and rent out commercial building properties) on potential ESG improvements and financing opportunities to make those improvements both workable and economical, is demonstrating its own success through a major jump in revenues from its operations. The company reported Nov. 14 that its quarterly income had grown 877 percent over the previous quarter from $236,690 to $2,312,577, due largely to completion of construction milestones in contracted projects. Year-over-year, Correlate Infrastructure’s revenues grew by nearly 15,024 percent. “We continue to make smart choices to optimize our organic project delivery based on a dynamic 2022 regulatory and supply chain landscape,” CEO Todd Michaels stated in the company’s Nov. 14 announcement (https://ibn.fm/1Jbdr). “The Inflation Reduction Act enacted in late August (by the federal government) provided new tax incentives that reduce costs for clients and/or elevate returns to investors; this led to larger contract sizes with redesigns to domestic content. While this meant delaying some project starts, it will be a big net gain, and will open new markets for us in 2023.” CIPI has another $16.2 million in unrecognized revenues in the pipeline for projects currently being installed at customer locations. All in all, the company currently has project opportunities valued at up to $194 million when projects in development are taken into consideration to include agreements that have been awarded but have not yet reached the executed contract stage. The figures indicate a measure of CIPI’s success in delivering advisory assistance on acquisitions and project development for environmentally friendly solutions, paired with infrastructure and financing resources. The company’s subsidiaries, Correlate, Inc. and Loyal Enterprises LLC (dba Solar Site Design), analyze utilities usage and provide data-driven recommendations for improvements to HVAC, mechanical, electrical and plumbing processes, the addition of solar upgrades, water optimization and antimicrobial airflow, the strategic procurement of energy sources, vehicle electrification and master controls that provide intelligent oversight of any retrofits. The availability of government subsidies and the discovery of other financial incentives helps round out the benefits the companies provide. Correlate’s growth points to the rising demand for its expertise. For more information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI